Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 12/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15836281 | 0.87 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL1586269 | 0.85 | NAPRT (0.49) | HCRTR1HCRTR2KDM4EKMT2ACASP6 | |
| SCHEMBL17069782 | 0.84 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL16025411 | 0.83 | HCRTR1 (0.46) | HCRTR1HCRTR2KDM4EKMT2ACASP6 | |
| SCHEMBL18163368 | 0.83 | HCRTR1 (0.46) | HCRTR1HCRTR2KDM4ECASP6 | |
| SCHEMBL8323880 | 0.83 | HCRTR1 (0.52) | HCRTR1HCRTR2KDM4CKMT2ACASP6 | |
| SCHEMBL20169442 | 0.83 | HCRTR1 (0.46) | HCRTR1HCRTR2KDM4ECASP6 | |
| SCHEMBL17449218 | 0.77 | KDM4C (0.57) | HCRTR1HCRTR2KDM4CKDM4EKMT2A | |
| SCHEMBL2645320 | 0.77 | MAPK14 (0.54) | KMT2AALDH1A1 | |
| SCHEMBL6215832 | 0.76 | PARP10 (0.39) | KDM4CMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765057-B2 | 3-ester-4 substituted orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9745284-B2 | 2-pyridyloxy-4-ether orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9586934-B2 | 2-pyridyloxy-4-methyl orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586950-B2 | 2-pyridyloxy-3-ester-4-nitrile orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160368898-A1 | 2-PYRIDYLOXY-4-METHYL OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160016935-A1 | 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20150322040-A1 | 3-ESTER-4 SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150252033-A1 | 2-PYRIDYLOXY-3-ESTER-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-09-10 | — | — | US | disclosed |
| WO-2014099697-A1 | 3-ESTER-4-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322040-A1 | 3-ESTER-4 SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | HCRTR1 2/4885HCRTR2 1/4885KDM4C 796/4885 |
| US-20150252033-A1 | 2-PYRIDYLOXY-3-ESTER-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NTSR2 | HCRTR1 2/4885HCRTR2 1/4885KDM4C 1106/4885 |
| US-20160368898-A1 | 2-PYRIDYLOXY-4-METHYL OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885KDM4C 617/4885 |
| US-20160016935-A1 | 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885KDM4C 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.